China as a Growing Research Base for Innovation in Medicines Development
- 27 Downloads
In the current context of China’s rapidly growing economy, multinational drug companies are investing significantly in research and development in China, a trend that has accelerated over the last 10 years. A robust regulatory framework, an abundance of highly equipped medical universities and large patient numbers in all therapy areas make China an increasingly attractive location to conduct clinical research. In addition, data from China are now accepted for inclusion in applications for market authorisation by regulatory agencies worldwide, including the Food and Drug Administration (FDA) in the US. Hence China is becoming an equal partner in global clinical development, a trend that is likely to grow significantly in the years to come.
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
- 3.Good clinical practice (SFDA order No. 3). Effective 2003 Sep 1 [online]. Available from URL: http://www.sfda.gov.cn [Accessed 2006 Sep 8]
- 4.Regulations for the Administration of Adverse Drug Reaction Reports and Monitoring (SFDA & MOH order No. 7). Effective 2003 Mar 4 [online]. Available from URL: http://www.sfda.gov.cn [Accessed 2006 Sep 8]
- 5.Drug Registration Regulation (SFDA order No.17). Effective 2005 May 1 [online]. Available from URL: http://www.sfda.gov.cn [Accessed 2006 Sep 8]